# Lefkofsky Eric P, CEO of Tempus AI, sells $7.7 million in stock

Tempus AI reported revenue up 83% YoY to $367.2M and an adjusted Q4 loss of $0.04/share versus an expected $0.20 loss. Diagnostics revenue rose 121.6% to $266.9M and Data & Applications revenue increased 25.1% to $100.4M, and the company announced an expanded multi-year collaboration with Merck. CEO/chairman Eric Lefkofsky indirectly sold 151,520 Class A shares on March 26 for $7.71M across multiple entities under a Rule 10b5-1 plan, while retaining substantial direct and indirect holdings. Analysts reacted mixedly: H.C. Wainwright raised its target to $95 (Buy) while Stifel cut its target to $60 (Hold).

Analysis

Tempus’s expanding pharma collaborations are a classic platform inflection: once a handful of large partners validate the product, revenue can shift from project-based to multi-year recurring contracts, creating high-margin annuity streams and meaningful uplift to EV/Revenue multiples if adoption scales. The second-order beneficiary is not just internal R&D teams at big pharmas but CROs and niche biomarker services whose budgets can be reallocated to platform access fees; that reallocation can compress margins across the incumbent services chain over 12–36 months.

On the cost side, the business faces persistent, scaling-driven outflows: sovereign and enterprise data governance, ongoing annotation and compute, and payer/reimbursement engineering—these are the levers that will determine GAAP leverage, not top-line growth alone. Regulatory shocks (data privacy rules, restrictions on de-identified dataset use) are low-probability but high-impact catalysts that could remove addressable market access quickly; conversely, a string of pharma implementations with demonstrable go/no-go outcomes would materially derisk the revenue multiple over 12–24 months.

Near-term price action is being driven by liquidity and narrative (insider plan executions, volatility), not by irreversible changes to the competitive moat; that creates tactical opportunities for asymmetric option structures and paired trades to express a conviction in platform economics while capping downside. Monitor partner-level KPIs (number of active joint projects, incremental contracted ARR, data refresh cadence) and margin progression in Data & Applications as the decisive read-throughs for a re-rating.

The consensus is underweighting the timing gap between contract wins and throughput-driven margin realization: successful partnerships can take multiple quarters to convert into high-margin revenue. That gap offers windows where downside is capped with defined-cost bullish exposure and where a short against legacy testing operators (whose volumes are exposed to reimbursement and price pressure) can pay off if platform adoption accelerates.

Key Decisions for Investors

• Core long: TEM — size 1.5% NAV. Build on a 10–20% volatility-led pullback; target 2x in 12–24 months if platform adoption metrics accelerate. Hard stop at -30% from entry (cut to cash) to limit regulatory/partner-risk exposure.
• Defined-cost bullish (options): Buy a 9–12 month call spread 40–60% OTM (delta-light structure) sized to risk 0.5% NAV; expected asymmetric upside 3:1 if pharma collaborations convert to contracted ARR within 12 months.
• Pair trade (market-neutral tilt): Long TEM 1% NAV / Short LH (LabCorp) 1% NAV. Rationale: capture re-rating of data-platform premium vs legacy diagnostic volume exposure over 6–18 months. Close if dispersion narrows to <5% relative performance or after two successive quarterly updates that show no incremental contracted wins.
• Event hedge: Buy 3–6 month puts (~10% notional of equity position) ahead of regulatory guidance windows or major partner milestones to protect against sudden de-risking. Expect this hedge to cost ~3–5% of position value but cap headline drawdowns from regime changes.